Latasha brings extensive experience in global clinical operations, with a focus on the execution of early- and late-phase oncology trials across complex therapeutic areas, including solid tumors, hematologic malignancies, and rare diseases. She has played key roles in supporting and leading global clinical programs across Phase I through Phase III, with responsibility for study start-up, execution, vendor oversight, and inspection readiness across multi-country trials.

 

Prior to joining K36 Therapeutics, Latasha served as Associate Director, Global Clinical Project Manager at IDRx, Inc., where she supported global clinical operations across a gastrointestinal stromal tumor (GIST) program, contributing to ongoing study execution and leading Phase III study start-up and readiness activities. She has also held roles at Forma Therapeutics and Constellation Pharmaceuticals, where she supported oncology and hematology studies, including programs focused on epigenetic therapies. 

 

Latasha is recognized for her ability to drive operational excellence in fast-paced environments, with strengths in cross-functional collaboration, risk management, and ensuring high standards of data quality and inspection readiness. She has also represented sponsors at patient advocacy events, strengthening engagement with patient communities and bringing a patient-centered perspective to clinical development.

 

She holds a Master of Science in Pharmacology from Northeastern University and a Bachelor of Science in Pharmacology and Toxicology from MCPHS University. She is a Certified Clinical Research Professional (CCRP®) and a Qualified TMF Manager.

​